On Monday, the European Union has given a green signal to the world’s first Ebola vaccine. The approval has marked a significant advancement in the mission to stop exposure to the fatal disease. Reportedly, European health authorities have approved the Ebola vaccine on conditional marketing authorization. Merck, a giant pharmaceutical company, has developed Ervebo, the vaccine to prevent Ebola. Also, it is a first-ever vaccine to gain approval from the EU.
The Public Health Agency of Canada and the American army had first formulated Ervebo around more than ten years ago. After that, Ebola struck West Africa in 2014. Thus it was essential for Merck to have rights for the development of the vaccine. As mentioned above, now the pharmaceutical giant has gained approval on conditional marketing authorization. It is a category of authorized medicines that overcome unsatisfied medical demands of patients. Even more, it permits the medication to progress with less extensive data than usually essential if the benefits exceed risks. It also means that the newly-approved Ebola vaccine relies on less comprehensive data than needful. Such types of drugs gain rapid approval than regular ones, thus need less clinical data to be gathered and studied for approval.
EU’s Commissioner of Health and Food Safety Vytenis Andriukaitis said it had been a priority for the international community to find a vaccine against the fatal virus as soon as possible. The official said the decision is a significant step to save lives in Africa and further on. Inventors of the vaccine, scientists from the Public Health Agency of Canada, still secure the non-commercial rights for Ervebo. Notably, experts are already using the jab under a matter of urgency to control the ongoing epidemic in Congo. According to the WHO, the vaccine has an impressive rate of 97.5%. Still, there are around 3,000 confirmed Ebola cases in the DRC, and the epidemic has slaughtered more than 2,100 people.